Semax Neuroprotective Effects: BDNF Upregulation, Stroke Recovery, and Cognitive Enhancement

Background

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the adrenocorticotropic hormone (ACTH) fragment 4-10, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike ACTH itself, Semax lacks hormonal (steroidogenic) activity while retaining potent neurotrophic and neuroprotective properties. The peptide has been approved in Russia and several CIS countries for the treatment of acute ischemic stroke, cognitive disorders, and optic nerve atrophy. Its primary mechanism of action involves the upregulation of brain-derived neurotrophic factor (BDNF) and other neurotrophins, positioning it at the intersection of neuroprotection and cognitive enhancement research.

Methods

Preclinical studies have utilized multiple experimental paradigms to evaluate Semax. In the study by Dolotov and colleagues (2006), Semax was administered intranasally at 50 and 250 micrograms per kilogram bodyweight to rats, and BDNF protein levels were measured in the basal forebrain, hippocampus, and cerebral cortex at various time points. A separate study by Agapova and colleagues assessed Semax-induced changes in neurotrophin and neurotrophin receptor gene expression following experimental cerebral ischemia using genome-wide RNA-Seq analysis. Clinical studies have evaluated Semax in patients with acute hemispheric ischemic stroke, with 30 treated patients compared against 80 controls receiving conventional therapy. Additional clinical investigations examined Semax for prevention of disease progression in patients with chronic cerebrovascular insufficiency.

Key Findings

BDNF Upregulation

Intranasal Semax administration at 50 and 250 micrograms per kilogram produced a rapid increase in BDNF protein levels in the rat basal forebrain within 3 hours. The effect was dose-dependent and regionally specific, with the basal forebrain — a region critical for cholinergic neurotransmission and memory formation — showing the most pronounced response. Temporal dynamics studies revealed that Semax differentially regulated BDNF and nerve growth factor (NGF) expression in the hippocampus, frontal cortex, and retina, with region-specific and time-dependent patterns.

Ischemic Neuroprotection

In rat models of cerebral ischemia, Semax suppressed the expression of inflammatory genes while activating neurotransmitter-related gene expression within 24 hours. The peptide prevented the pathological rise in nitric oxide production that accompanies ischemic injury, a mechanism distinct from its neurotrophic effects. Proteomic analysis confirmed that Semax modulated brain protein expression profiles consistent with neuroprotection, including upregulation of CREB (cAMP response element-binding protein) in subcortical structures.

Stroke Recovery

In the clinical study of acute ischemic stroke, Semax added to standard intensive therapy accelerated the regression of general cerebral symptoms and focal neurological deficits, particularly motor disorders. Intranasal administration of Semax for 6 days in a rat model decreased the volume of cortical infarction and improved retention and performance of conditioned passive avoidance response, indicating preserved learning and memory function.

Cognitive Enhancement

Semax has demonstrated effects on learning and memory formation in both rodent and human studies. The peptide's cognitive effects appear to be mediated, at least in part, through increased BDNF levels in memory-associated brain regions. In patients with chronic cerebrovascular insufficiency, Semax treatment resulted in clinical stabilization, reduced progression of cognitive decline, and decreased risk of stroke and transient ischemic attacks.

Implications

Semax offers a compelling example of a peptide therapeutic with well-characterized neurotrophic mechanisms and established clinical use in stroke and cognitive disorders. Its ability to rapidly increase BDNF in memory-critical brain regions through simple intranasal delivery addresses a key challenge in neurotherapeutics — central nervous system drug delivery. The convergence of preclinical mechanistic data and clinical efficacy evidence provides a stronger translational foundation than is available for most neuropeptide candidates.

Limitations

The majority of clinical evidence for Semax originates from Russian-language publications and clinical practice, with limited representation in Western peer-reviewed literature. Large-scale, multicenter, double-blind, placebo-controlled trials meeting current international standards (ICH-GCP) have not been conducted. The peptide's regulatory status outside of Russia and the CIS remains unapproved. While BDNF upregulation is a plausible mechanism, the precise molecular targets through which Semax exerts its effects are not fully elucidated. Long-term safety data from large populations are limited.